Bakunang COVID-19 ng Pfizer–BioNTech: Pagkakaiba sa mga binago

Content deleted Content added
Ivan P. Clarin (usapan | ambag)
mNo edit summary
Ivan P. Clarin (usapan | ambag)
No edit summary
Linya 11:
| caption = A vial of the Pfizer–BioNTech COVID‑19 vaccine
| pronounce =
| tradename = Comirnaty<ref name="Swiss authorization" /><ref name="Comirnaty EPAR" /><ref name="Comirnaty global" />
| Drugs.com =
| MedlinePlus =
Linya 18:
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU = B1
| pregnancy_AU_comment =
| pregnancy_AU_comment = <ref>{{cite web|title=Comirnaty|url=https://www.tga.gov.au/apm-summary/comirnaty|access-date=25 January 2021|website=[[Therapeutic Goods Administration]] (TGA)}}</ref>
| pregnancy_category =
| routes_of_administration = [[Intramuscular injection|Intramuscular]]
Linya 25:
| ATC_supplemental =
| legal_AU = S4
| legal_AU_comment =
| legal_AU_comment = <ref>{{cite web | title=Comirnaty (BNT162b2 [mRNA]) COVID‑19 Vaccine Product Information | website=[[Therapeutic Goods Administration]] (TGA) | url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2021-PI-01092-1 | format=PDF | access-date=25 January 2021}}</ref><ref>{{cite report | url=https://www.tga.gov.au/sites/default/files/auspar-bnt162b2-mrna-210125.pdf | title=Australian Public Assessment Report for BNT162b2 (mRNA) | publisher=[[Therapeutic Goods Administration]] (TGA) | access-date=25 January 2021}}</ref>
| legal_BR =
| legal_BR_comment =
| legal_CA = Schedule D; Authorized by interim order
| legal_CA_comment = <ref name= "hcreg"/><ref name="CA Pfizer-BioNTech product description" />
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
Linya 35:
| legal_NZ_comment =
| legal_UK = Conditional and temporary authorization to supply
| legal_UK_comment =
| legal_UK_comment = <ref name="MHRA product information" /><ref>{{cite web | title=Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine | website=[[Medicines and Healthcare products Regulatory Agency]] (MHRA) | date=31 December 2020 | url=https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/conditions-of-authorisation-for-pfizerbiontech-covid-19-vaccine | access-date=8 January 2021}}</ref>
| legal_US = Standing Order; Unapproved
| legal_US_comment =
Linya 60:
}}
 
Ang '''Pfizer–BioNTech''', ay isa sa mga bakuna laban sa [[COVID-19]] sa mundo ay mula sa '''BioNTech''' mula sa Mainz, Rhineland-Palatinate, [[Alemanya]]. Ito ay inaprubahan ng [[World Health Organization]] (WHO).<ref>https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine</ref>
 
Ang Pfizer BioNTech COVID-19 ay isang hindi naaprubahang bakuna na maaaringmakapigil sa pagkakaroon ng COVID-19. Walang bakuna na inaprubahan ng FDA upang maiwasan ang COVID-19. <ref>https://www.pfizer.com/news/hot-topics/the_facts_about_pfizer_and_biontech_s_covid_19_vaccine</ref>
 
Pinahintulutan ng FDA ang emerhensiya paggamit ng Bakuna na Pfizer BioNTech COVID-19 upang maiwasan ang COVID-19 sa mga indibidwal na 12 taong gulang pataas sa ilalim ng Emergency Use Authorization (EUA).<ref>https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against</ref>
 
==Paggamit==
Ang Bakunang Pfizer-BioNTech COVID-19 ay isang bakunang hindi inaprubahan. Sa mga klinikal na pagsubok, humigit-kumulang 23,000 na mga indibidwal na 12 taong gulang pataas ang nakatanggap ng hindi bababa sa 1 dosis ng Bakuna na Pfizer-BioNTech COVID-19.<ref>https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine</ref>
 
===Mga panganib ng Pfizer–BioNTech===